Literature DB >> 31410492

Dermatofibrosarcoma Protuberans Re-excision and Recurrence Rates in the Netherlands Between 1989 and 2016.

Charlotte B van Lee1, Wilner Christopher Kan, Sonia Gran, Antien Mooyaart, Marc A M Mureau, Hywel C Williams, Rubeta Matin, Renate van den Bos, Loes M Hollestein.   

Abstract

Dermatofibrosarcoma protuberans is a rare soft tissue tumour with a very low (p < 0.5%) rate of metastasis. Rates of re-excision and recurrence were determined using data from the Netherlands Cancer Registry between 1989 and 2016. Of the 1,890 instances of dermatofibrosarcoma protuberans included, 87% were treated with excision, 4% with Mohs micrographic surgery, and 9% otherwise or unknown. Linked pathology data were retrieved for 1,677 patients. Half of all excisions (847/1,644) were incomplete and 29% (192/622) of all re-excisions were incomplete. The cumulative incidence of a recurrence was 7% (95% confidence interval (95% CI) 6-8) during a median follow-up of 11 years (interquartile range (IQR) 6-17). After Mohs micrographic surgery (n = 34), there were no recurrences during a median follow-up of 4 years (IQR 3-6). Due to the high rate of incomplete excisions and recurrences after excision, this study supports the European guideline, which recommends treating dermatofibrosarcoma protuberans with Mohs micrographic surgery in order to decrease the rate of recurrence.

Entities:  

Keywords:  Mohs micrographic surgery; histological clearance; recurrence; surgical excision; dermatofibrosarcoma protuberans

Mesh:

Year:  2019        PMID: 31410492     DOI: 10.2340/00015555-3287

Source DB:  PubMed          Journal:  Acta Derm Venereol        ISSN: 0001-5555            Impact factor:   3.875


  3 in total

1.  Surgical Outcomes of Primary Dermatofibrosarcoma Protuberans: A Retrospective, Multicenter Study.

Authors:  Matthew T Houdek; Kim M Tsoi; Katherine E Mallett; Ryan M Claxton; Peter C Ferguson; Anthony M Griffin; Christian L Baum; Jerry D Brewer; Peter S Rose; Jay S Wunder
Journal:  Ann Surg Oncol       Date:  2022-08-06       Impact factor: 4.339

2.  Clinical Outcome of Dermatofibrosarcoma Protuberance. Report From the Bone and Soft Tissue Tumor (BSTT) Registry in Japan.

Authors:  Tomoki Nakamura; Akira Kawai; Kunihiro Asanuma; Tomohito Hagi; Akihiro Sudo
Journal:  In Vivo       Date:  2021 Jan-Feb       Impact factor: 2.406

3.  The Ki-67 proliferation index predicts recurrence-free survival in patients with dermatofibrosarcoma protuberans.

Authors:  Deligonul Adem; Serkan Yazici; Mine Ozsen; Sibel Kahraman Cetintas; Ulviye Yalcinkaya; Ahmet Bilgehan Şahin; Ozgur Tanrıverdi; Sibel Oyucu Orhan; Birol Ocak; Erdem Cubukcu; Ramazan Kahveci; Turkkan Evrensel
Journal:  Bosn J Basic Med Sci       Date:  2021-04-01       Impact factor: 3.363

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.